Australian Clinical Labs (ASX:ACL)
ASX announcement history & article coverage
Transparent by design.
Announcments by Australian Clinical Labs (ASX:ACL) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Becoming a substantial holder
Ceasing to be a substantial holder
Becoming a substantial holder
Ceasing to be a substantial holder
Correction to Notice of Meeting for 2026 AGM
Becoming a substantial holder
Change of Auditor
Appendix 4G
2026 Annual Report
ACL reports resilient FY26 earnings, issues FY27 guidance and confirms CEO transition
Notice of meeting - 2026 AGM
Change in substantial holding
Change of Director's Interest Notice - S Butler
Initial Director's Interest Notice - G Horan
Final Director's Interest Notice - M McGrath
Notification regarding unquoted securities - ACL
Notification regarding unquoted securities - ACL
Notification of cessation of securities - ACL
Ceasing to be a substantial holder
Change in substantial holding from MUFG
Change in substantial holding
Ceasing to be a substantial holder
Dividend/Distribution - ACL
Australian Clinical Labs declares fully franked dividend of AUD 0.0925 per share for H1 2026
FY26 financial results investor presentation
Australian Clinical Labs reports FY26 EBIT growth and margin expansion; FY27 guidance reflects stable margins amid market challenges
Appendix 4E and FY26 financial reports
Australian Clinical Labs reports FY26 results with mixed earnings, dividend increase, and strategic growth plans amid market challenges
FY26 Results Investor Webinar
Date of 2026 AGM
Becoming a substantial holder